

MDPI

Article

# Acupuncture Is Effective at Reducing the Risk of Stroke in Patients with Migraines: A Real-World, Large-Scale Cohort Study with 19-Years of Follow-Up

Chung-Chih Liao 1,†, Chi-Hsien Chien 1,†, Ying-Hsiu Shih 2,3, Fuu-Jen Tsai 4,5,6,7 and Jung-Miao Li 4,8,\*

- Department of Post-Baccalaureate Veterinary Medicine, Asia University, Taichung 41354, Taiwan
- Management Office for Health Data, China Medical University Hospital, Taichung 40201, Taiwan
- College of Medicine, China Medical University, Taichung 40402, Taiwan
- School of Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung 40402, Taiwan
- Department of Medical Research, China Medical University Hospital, China Medical University, Taichung 40402, Taiwan
- Division of Medical Genetics, China Medical University Children's Hospital, Taichung 40447, Taiwan
- Department of Biotechnology and Bioinformatics, Asia University, Taichung 41354, Taiwan
- Department of Chinese Medicine, China Medical University Hospital, Taichung 40447, Taiwan
- \* Correspondence: rungmiau0212@gmail.com; Tel.: +886-4-22053366 (ext. 3102)
- † These authors contributed equally to this work.

**Abstract:** Migraines are common headache disorders and risk factors for subsequent strokes. Acupuncture has been widely used in the treatment of migraines; however, few studies have examined whether its use reduces the risk of strokes in migraineurs. This study explored the long-term effects of acupuncture treatment on stroke risk in migraineurs using national real-world data. We collected new migraine patients from the Taiwan National Health Insurance Research Database (NHIRD) from 1 January 2000 to 31 December 2017. Using 1:1 propensity-score matching, we assigned patients to either an acupuncture or non-acupuncture cohort and followed up until the end of 2018. The incidence of stroke in the two cohorts was compared using the Cox proportional hazards regression analysis. Each cohort was composed of 1354 newly diagnosed migraineurs with similar baseline characteristics. Compared with the non-acupuncture cohort, the acupuncture cohort had a significantly reduced risk of stroke (adjusted hazard ratio, 0.4; 95% confidence interval, 0.35–0.46). The Kaplan–Meier model showed a significantly lower cumulative incidence of stroke in migraine patients who received acupuncture during the 19-year follow-up (log-rank test, p < 0.001). Acupuncture confers protective benefits on migraineurs by reducing the risk of stroke. Our results provide new insights for clinicians and public health experts.

Keywords: migraine; stroke; acupuncture; National Health Insurance Research Database



Citation: Liao, C.-C.; Chien, C.-H.; Shih, Y.-H.; Tsai, F.-J.; Li, J.-M. Acupuncture Is Effective at Reducing the Risk of Stroke in Patients with Migraines: A Real-World, Large-Scale Cohort Study with 19-Years of Follow-Up. *Int. J. Environ. Res. Public Health* 2023, 20, 1690. https:// doi.org/10.3390/ijerph20031690

Academic Editor: Maria Esposito

Received: 7 December 2022 Revised: 9 January 2023 Accepted: 15 January 2023 Published: 17 January 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

## 1. Introduction

Migraines are common neurovascular disorders affecting more than 1 billion people worldwide and are the second most disabling disease globally [1,2]. In addition to the unbearable unilateral, throbbing headache, a migraine may also be accompanied by symptoms, such as nausea and/or vomiting or photophobia and/or phonophobia, which often seriously affect a person's quality of work and life [3]. Currently, migraines are mainly treated with pharmacological therapy. The treatment goal is to relieve the pain symptoms of acute headaches, and reduce the frequency of attacks and rate of recurrence, thus enabling the patient's return to normal work and life as quickly as possible [4]. However, some patients have poor tolerance to oral medications, and the unpleasant side effects and lower-than-expected efficacy of these medications may lead to low treatment compliance and other complications, causing some patients to choose acupuncture therapy [5].

Strokes, including ischemic and hemorrhagic strokes, are the leading causes of death and disability worldwide. According to one survey, the global lifetime risk of a stroke at age 25 and older is about 25% in both men and women [6]. Even if a patient survives a stroke, he/she is usually left with some degree of neurological deficit, which often imposes a heavy life and financial burden on both patients and their caregivers.

There is growing evidence that migraines increase the risk of strokes. A migraine with aura is considered a risk factor for ischemic stroke, while high frequency and recent onset of migraine are also associated with an increased risk of ischemic stroke [7]. A nationwide population-based study concluded that migraines are associated with an increased risk of ischemic stroke, especially in young (age  $\leq 45$  years) women with migraines with aura [8]. In another recent study, both a migraine without aura and a migraine with aura were associated with an increased risk of a stroke compared with non-migraineurs (adjusted hazard ratio (aHR) 1.49 and 1.63, respectively) [9]. However, there is currently no direct evidence to support that the preventive medication treatment recommended for use reduces future stroke attacks in migraineurs [7,10].

Acupuncture therapy is one of the main treatment techniques of traditional Chinese medicine. It has a history spanning more than 3000 years and is now widely used in countries all over the world. Acupuncture is considered to be an effective alternative therapy for migraines [11]. An overview of systematic reviews concluded that acupuncture leads to a higher reduction in the number of days with headaches and the use of pain medication, and is more effective at reducing headache frequency and severity, than the same parameters associated with Western medicine and sham acupuncture [12]. A randomized clinical trial concluded that acupuncture treatment was more efficient than sham acupuncture or no acupuncture treatment in reducing long-term recurrent migraine in patients with migraines without aura [13]. Furthermore, in one study, patients in the group receiving real acupuncture were significantly better at controlling pain levels and improving quality of life with chronic migraines than those in the sham acupuncture group [14]. Another study revealed that preventive acupuncture in patients with chronic migraine significantly reduced the average number of moderate/severe headache days per month compared with the change associated with topiramate treatment [15]. In addition, a growing number of clinical trials have shown that acupuncture, when used in stroke therapy, provides excellent complementary and alternative therapy for post-stroke rehabilitation; it also serves as a preventive strategy that induces cerebral ischemic tolerance [16–19]. Therefore, we investigated whether acupuncture could provide long-term protection against strokes in patients with migraines.

To date, there has been no large-scale real-world evidence to show whether acupuncture is beneficial in reducing the risk of subsequent strokes in migraineurs. Therefore, we conducted a cohort study using a national database to explore the relationship between acupuncture intervention and stroke development in patients with migraines.

# 2. Materials and Methods

# 2.1. Data Source

The study used the Longitudinal Generation Tracking Database 2005 (LGTD 2005) for a nationwide, population-based cohort analysis. The dataset contained all claims data from a random sample of 2,000,000 from the National Health Insurance Research Database (NHIRD) in Taiwan. In LGTD 2005, in order to protect personal privacy, scrambled, anonymous identification numbers were used, and detailed medical information related to traditional Chinese medicine and western medicine was recorded, such as demographic characteristics, medical visits, doctor's diagnosis, prescription drugs, surgical procedures, and medical expenditure from 2000 to 2018. The International Classification of Diseases, Ninth Revision and Tenth Revision, Clinical Modification (ICD-9-CM and ICD-10-CM) was used for the diagnosis codes. The Institutional Review Board of the China Medical University in central Taiwan (CMUH110-REC1-038(CR-1)) approved this study.

# 2.2. Study Population

We enrolled all participants newly diagnosed with migraines (ICD-9-CM: 346 or ICD-10-CM code: G43.109, G43.501, G43.509, G43.601, G43.609, G43.101, G43.111, G43.119, G43.511, G43.519, G43.611, G43.619, G43.009, G43.011, G43.019, G43.711, G43.719, G43.801, G43.809, G43.A0, G43.B0, G43.C0, G43.D0, G44.001, G44.009, G44.011, G44.019, G44.021, G44.029, G43.811, G43.819, G43.A1, G43.B1, G43.C1, G43.D1, G43.401, G43.409, G43.411, G43.419, G43.701, G43.709, G43.901, G43.909, G44.031, G44.039, G44.041, G44.049, G44.51, G43.911, G43.919), with at least two outpatients or hospitalizations from 1 January 2000, to 31 December 2018, in the LGTD 2005 (n = 123,691). Patients who received acupuncture after the new migraine diagnosis date were defined as acupuncture users, while the remaining patients were defined as acupuncture non-users. In addition, the date of receiving the first acupuncture treatment after the new diagnosis date of the migraine was defined as the index date for the acupuncture cohort. Regarding the index date for the acupuncture non-users, we randomly assigned a month and day to the same index year of the matched acupuncture cases. We excluded subjects aged < 20 years (n = 3540), index date after 31 December 2017 (n = 18,362), and those with a history of stroke (ICD-9-CM 430–438 or ICD-10-CM: I60-I69) before the index date (n = 9976). The 1:1 propensity score method by sex, age, urbanization level, occupation, monthly income, baseline comorbidities, and medication was used to match an equal number of patients in both cohorts. The research process is shown in Figure 1. The primary outcome of the study was the incidence of stroke (ICD-9-CM 430-438 or ICD-10-CM: I60-I69), as diagnosed by a nationally certified neurologist. The follow-up period in both cohorts started from the index date until diagnosis with stroke, death, withdrawal from the National Health Insurance (NHI) program, or the end of 2018. Baseline comorbidities were considered to exist, including diabetes mellitus, hypertension, hyperlipidemia, coronary artery disease, head injury, Parkinson's disease, chronic kidney disease, and mental disorders. Medication usage was defined as the first prescribed medication after migraine and included triptans, ergots, acetaminophen, NSAIDs (including etoricoxib, celecoxib, and ibuprofen), propranolol, flunarizine, antiepileptics (including valproic acid and topiramate), and amitriptyline. Patient medication usage was classified (into groups) as those taking 0-1, 2-3, or >3 medications, according to the accumulated number of medications prescribed throughout the follow-up.




Figure 1. Study flowchart. LGTD 2005: Longitudinal Generation Tracking Database 2005.

# 2.3. Statistical Analysis

Differences in baseline characteristics between both groups were examined using the standardized mean difference (SMD). A standardized mean difference of 0.1 or less indicates a negligible difference. The incidence density rates of strokes were calculated for both acupuncture and non-acupuncture cohorts. Univariable and multivariable Cox proportional hazard regressions were performed to evaluate the hazard ratios (HRs) with 95% confidence intervals (CIs) for strokes. The Kaplan–Meier method was used to estimate the differences in the cumulative incidence of strokes between the two cohorts by the log-rank test. A *p*-value of less than 0.05 indicated statistical significance. All statistical analyses and figures were performed using SAS software, version 9.4 (SAS Institute, Inc., Cary, NC, USA), and survival curves were drawn using R software (R version 4.2.0).

### 3. Results

The study randomly selected 1354 patients in the acupuncture and non-acupuncture cohorts using the 1:1 propensity score-matching method. Table 1 presents the baseline characteristics of both cohorts. In terms of sex, age, urbanization level, occupation, income, baseline comorbidities, and medication use, there were no significant differences between the cohorts. The ratio of females to males was about 7:3. Regarding the age subgroups, the highest proportion of migraine sufferers in both groups was in the 40–59 age group, with a mean age of about 47 years. The most common baseline comorbidities in both groups were mental disorders (44%), followed by hypertension (25%), and hyperlipidemia (14%). Most migraine sufferers (52%) took two to three different medications. The average follow-up time for stroke was 13.77 years in the acupuncture cohort and 9.71 years in the non-acupuncture cohort.

**Table 1.** Characteristics of new migraine patients who did or did not receive acupuncture.

	Migraine witho	out Acupuncture	Migraine witl		
	N =	1354	N =		
Characteristic	n	%	n	%	SMD
Sex					
female	967	71.42	992	73.26	0.041
male	387	28.58	362	26.74	0.041
Age, year					
20–39	428	31.61	440	32.50	0.019
40-59	582	42.98	651	48.08	0.102
>59	344	25.41	263	19.42	0.144
mean, (SD)	48.25	15.44	46.67	14.24	0.107
Urbanization level <sup>‡</sup>					
Low	774	57.16	780	57.61	0.009
Medium	464	34.27	463	34.20	0.002
High	116	8.57	111	8.20	0.013
Occupation					
Office worker	562	41.51	597	44.09	0.052
Laborer	581	42.91	564	41.65	0.025
Others &	211	15.58	193	14.25	0.037
Income †					
<20,000	950	70.16	925	68.32	0.04
20,000–39,999	290	21.42	322	23.78	0.057
>39,999	114	8.42	107	7.90	0.019
Comorbidities					0.0-7
Diabetes mellitus	110	8.12	101	7.46	0.025
Hypertension	372	27.47	334	24.67	0.064
Hyperlipidemia	185	13.66	183	13.52	0.004
Coronary artery disease	174	12.85	155	11.45	0.043
Head injury	39	2.88	44	3.25	0.021
Parkinson's disease	8	0.59	11	0.81	0.027
Chronic kidney disease	70	5.17	59	4.36	0.038
Mental disorders	603	44.53	592	43.72	0.016
Medication					
0–1	159	11.74	143	10.56	0.038
2–3	703	51.92	709	52.36	0.009
>3	492	36.34	502	37.08	0.015
Mean follow-up years, (SD)	9.71	7.41	13.77	6.01	0.602

Chi-square test; *t*-test. SMD: standardized mean difference. A standardized mean difference of 0.1 or less indicates a negligible difference. <sup>†</sup> New Taiwan Dollar (NTD), 1 NTD is equal to 0.03 USD. <sup>‡</sup> The urbanization level was divided by the population density of the residential area into 3 levels, where level 1 was the most urbanized and level 3 was the least urbanized. <sup>&</sup> Other occupation categories included those who were primarily retired, unemployed, and low-income populations.

Table 2 shows the crude and adjusted HRs for stroke and covariates in migraineurs. Among patients with migraines, 387 patients (20.76 per 1000 person-years) who received acupuncture and 636 patients (48.38 per 1000 person-years) who did not receive acupuncture had strokes during the follow-up. In a Cox proportional hazards model, after adjusting for sex, age, urbanization level, occupation, income, baseline comorbidities, and medication use, migraineurs receiving acupuncture had a significantly lower risk of strokes than acupuncture non-users (aHR, 0.4; 95% CI, 0.35–0.46). There was no significant difference in the risk of stroke development between males and females with migraines (males vs. females: aHR, 1.02; 95% CI, 0.88-1.17). Among patients with migraines, the risk of a stroke exhibited a dose-dependent increase with advancing age (aHR, 2.55; 95% CI, 2.1-3.09 for patients aged 40-59 years vs. 20-39 years; aHR, 4.93; 95% CI, 4-6.09 for patients aged >59 years vs. 20–39 years). Hypertension, coronary artery disease, head injury, Parkinson's disease, and mental disorders were baseline comorbidities that increased the risk of a stroke. Patients with migraines who took more medications had a dose-dependent lower risk of a stroke (aHR, 0.18; 95% CI, 0.15–0.21 for 2–3 medications vs. 0–1 medication; aHR, 0.11; 95% CI, 0.09-0.13 for >3 medications vs. 0-1 medication).

**Table 2.** Hazard ratios (HRs), and 95% confidence intervals (CIs) of strokes with covariates among patients with migraines in multivariable Cox proportional hazards regression.

		Stroke					
Variables	n	PY	PY IR		(95% CI)	aHR †	(95% CI)
Migraine without acupuncture	636	13,145	48.38	1.00	(Reference)	1.00	(Reference)
Migraine with acupuncture	387	18,644	20.76	0.47	(0.41, 0.53) ***	0.4	(0.35, 0.46) ***
Sex							
female	721	23,767	30.34	1.00	(Reference)	1.00	(Reference)
male	302	8022	37.65	1.2	(1.05, 1.37) **	1.02	(0.88, 1.17)
Age, year							
20–39	147	12,950	11.35	1.00	(Reference)	1.00	(Reference)
40-59	478	14,875	32.13	2.65	(2.2, 3.18) ***	2.55	(2.1, 3.09) ***
>59	398	3964	100.41	6.71	(5.54, 8.12) ***	4.93	(4, 6.09) ***
Urbanization level <sup>‡</sup>							
Low	577	18,627	30.98	1.00	(Reference)	1.00	(Reference)
Medium	362	10,573	34.24	1.08	(0.95, 1.23)	1.03	(0.9, 1.18)
High	84	2589	32.44	1.03	(0.82, 1.3)	0.91	(0.72, 1.14)
Occupation							
Office worker	343	15,433	22.23	1.00	(Reference)	1.00	(Reference)
Laborer	511	12,076	42.32	1.77	(1.54, 2.03) ***	1.32	(1.1, 1.58) **
Others &	169	4280	39.49	1.67	(1.39, 2.01) ***	1.26	(1, 1.58) *
Income #							
<20,000	752	21,057	35.71	1.00	(Reference)	1.00	(Reference)
20,000–39,999	196	8037	24.39	0.71	(0.61, 0.84) ***	1	(0.82, 1.21)
>39,999	75	2694	27.84	0.8	(0.63, 1.01)	0.8	(0.6, 1.06)
Comorbidities							
Diabetes mellitus	115	1735	66.27	1.88	(1.55, 2.28) ***	1.14	(0.93, 1.41)
Hypertension	409	6008	68.07	2.48	(2.18, 2.81) ***	1.4	(1.22, 1.61) ***
Hyperlipidemia	194	3653	53.11	1.67	(1.43, 1.95) ***	1.09	(0.92, 1.3)
Coronary artery disease	199	2590	76.83	2.32	(1.98, 2.71) ***	1.32	(1.11, 1.56) **
Head injury	37	832	44.48	1.32	(0.95, 1.83)	1.66	(1.19, 2.31) **
Parkinson's disease	15	104	144.25	3.5	(2.1, 5.83) ***	3.34	(1.98, 5.62) ***
Chronic kidney disease	66	1075	61.42	1.71	(1.33, 2.19) ***	1.06	(0.82, 1.37)
Mental disorders	525	13,124	40.00	1.43	(1.27, 1.62) ***	1.47	(1.29, 1.68) ***

mm 1 1		_	0 1
Tah	Α	"	Cont.

		Stroke					
Variables	n	n PY		cHR	(95% CI)	aHR <sup>†</sup>	(95% CI)
Medication							
0–1	214	1524	140.45	1.00	(Reference)	1.00	(Reference)
2–3	522	16,412	31.81	0.26	(0.22, 0.3) ***	0.18	(0.15, 0.21) ***
>3	287	13,854	20.72	0.17	(0.15, 0.21) ***	0.11	(0.09, 0.13) ***

PY: person-years; IR: incidence rate per 1000 person-years; cHR: crude hazard ratio; aHR: adjusted hazard ratio; dijusted by sex, age, urbanization level, occupation, income, comorbidities, and medication; \*: p-value < 0.05; \*\* p < 0.01, \*\*\* p < 0.001 \*\* New Taiwan Dollar (NTD), 1 NTD is equal to 0.03 USD. † The urbanization level was divided by the population density of the residential area into 3 levels, in which level 1 was the most urbanized and level 3 was the least urbanized. & Other occupation categories included those who were primarily retired, unemployed, and low-income populations.

Table 3 displays the incidence rates and HRs of strokes in acupuncture users compared to acupuncture non-users stratified by sex, age, urbanization level, occupation, income, baseline comorbidities, and medication use. The beneficial effect of receiving acupuncture treatment on stroke incidence was observed in both female and male migraine patients (aHR, 0.37; 95% CI, 0.32–0.43 for females; aHR, 0.32; 95% CI, 0.25–0.41 for males). Acupuncture reduced the risk of strokes in patients in all age groups and in patients who did or did not have baseline comorbidities. Patients in the acupuncture cohort using any drug doses were less likely to have strokes than those in the non-acupuncture cohort.

We further compared the incidence rate of stroke for ischemic and hemorrhagic strokes. The results in Table 4 show that, compared with non-acupuncture patients, patients who received acupuncture had a lower risk of these types of strokes.

Figure 2 shows that—using the Kaplan–Meier analysis—the cumulative incidence of strokes in patients with migraines was significantly lower in the acupuncture users than in the acupuncture non-users during the 19-year follow-up period (log-rank test, p < 0.001).




Figure 2. Cumulative incidence of strokes in the acupuncture and non-acupuncture cohorts.

Int. J. Environ. Res. Public Health **2023**, 20, 1690

**Table 3.** Incidence rates, hazard ratios (HRs), and 95% confidence intervals (CIs) of strokes for migraine patients who did and did not receive acupuncture treatment in different stratifications.

Migraine without Acupuncture			Migraine with Acupuncture								
N	PY	IR	n	PY	IR	cHR	cHR (95% CI)	<i>p-</i> Value	aHR †	(95% CI)	<i>p-</i> Value
450	9789	45.97	271	13,979	19.39	0.46	(0.39, 0.53) ***	< 0.001	0.37	(0.32, 0.43) ***	< 0.001
186	3356	55.42	116	4665	24.87	0.5	(0.4, 0.63) ***	< 0.001	0.32	(0.25, 0.41) ***	< 0.001
94	5898	15.94	53	7052	7.52	0.49	(0.35, 0.69) ***	< 0.001	0.32	(0.22, 0.46) ***	< 0.001
295	5635	52.35	183	9240	19.81	0.41	(0.34, 0.5) ***	< 0.001	0.35	(0.29, 0.42) ***	< 0.001
247	1612	153.26	151	2352	64.20	0.5	(0.41, 0.62) ***	< 0.001	0.37	(0.3, 0.46) ***	< 0.001
							, ,			, ,	
368	7747	47.50	209	10,880	19.21	0.44	(0.37, 0.53) ***	< 0.001	0.33	(0.28, 0.39) ***	< 0.001
218	4280	50.93	144		22.88	0.49		< 0.001	0.38		< 0.001
			34				` ' '			` ' '	0.4496
							(,			(====, ====,	
214	6442	33.22	129	8991	14.35	0.46	(0.37, 0.58) ***	< 0.001	0.3	(0.23, 0.38) ***	< 0.001
							, ,			, ,	< 0.001
											< 0.001
							(,			(,,	
471	8692	54.19	281	12,365	22.73	0.47	(0.4. 0.54) ***	< 0.001	0.36	(0.31, 0.43) ***	< 0.001
										, ,	< 0.001
							, ,				< 0.001
10	1100	11.10	_,	102,	17.07	0.10	(0.0) 0.1 0)	0.0021	0.2	(0.10) 0.02)	10.001
566	12 520	45 21	342	17 534	19 50	0.47	(0.41, 0.54) ***	< 0.001	0.37	(0.32 0.43) ***	< 0.001
							, ,			, ,	< 0.001
7.0	028	111.71	10	1110	10.00	0.10	(0.2), 0.02)	10.001	0.20	(0.10) 0.1)	10.001
377	10.918	34.53	237	14.863	15.95	0.49	(0.42, 0.58) ***	< 0.001	0.39	(0.33, 0.46) ***	< 0.001
											< 0.001
		110.20	100	0,01	07107	0.11	(0.01) 0.0)	10.001	0.0	(0.21) 0.01)	10.001
523	11.739	44.55	306	16.397	18.66	0.46	(0.4, 0.53) ***	< 0.001	0.34	(0.3, 0.4) ***	< 0.001
										, , ,	< 0.001
110	1100	00.00	01	2211	00.00	0.01	(0.00, 0.00)	VO.001	0.07	(0.27, 0.01)	<b>\0.001</b>
520	12 054	43 14	304	17 145	17 73	0.45	(0.39, 0.52) ***	<0.001	0.35	(0.3, 0.41) ***	< 0.001
							, ,			, , ,	< 0.001
	N  450 186  94 295 247	N PY  450 9789 186 3356  94 5898 295 5635 247 1612  368 7747 218 4280 50 1118  214 6442 315 4907 107 1797  471 8692 117 3285 48 1168  566 12,520 70 625  377 10,918 259 2227  523 11,739 113 1406  520 12,054	N PY IR  450 9789 45.97 186 3356 55.42  94 5898 15.94 295 5635 52.35 247 1612 153.26  368 7747 47.50 218 4280 50.93 50 1118 44.73  214 6442 33.22 315 4907 64.20 107 1797 59.55  471 8692 54.19 117 3285 35.62 48 1168 41.10  566 12,520 45.21 70 625 111.91  377 10,918 34.53 259 2227 116.28  523 11,739 44.55 113 1406 80.36  520 12,054 43.14	N         PY         IR         n           450         9789         45.97         271           186         3356         55.42         116           94         5898         15.94         53           295         5635         52.35         183           247         1612         153.26         151           368         7747         47.50         209           218         4280         50.93         144           50         1118         44.73         34           214         6442         33.22         129           315         4907         64.20         196           107         1797         59.55         62           471         8692         54.19         281           117         3285         35.62         79           48         1168         41.10         27           566         12,520         45.21         342           70         625         111.91         45           377         10,918         34.53         237           259         2227         116.28         150           523         1	N         PY         IR         n         PY           450         9789         45.97         271         13,979           186         3356         55.42         116         4665           94         5898         15.94         53         7052           295         5635         52.35         183         9240           247         1612         153.26         151         2352           368         7747         47.50         209         10,880           218         4280         50.93         144         6293           50         1118         44.73         34         1471           214         6442         33.22         129         8991           315         4907         64.20         196         7169           107         1797         59.55         62         2483           471         8692         54.19         281         12,365           117         3285         35.62         79         4752           48         1168         41.10         27         1527           566         12,520         45.21         342         17,534	N         PY         IR         n         PY         IR           450         9789         45.97         271         13,979         19.39           186         3356         55.42         116         4665         24.87           94         5898         15.94         53         7052         7.52           295         5635         52.35         183         9240         19.81           247         1612         153.26         151         2352         64.20           368         7747         47.50         209         10,880         19.21           218         4280         50.93         144         6293         22.88           50         1118         44.73         34         1471         23.11           214         6442         33.22         129         8991         14.35           315         4907         64.20         196         7169         27.34           107         1797         59.55         62         2483         24.97           471         8692         54.19         281         12,365         22.73           117         3285         35.62         79	N         PY         IR         n         PY         IR         cHR           450         9789         45.97         271         13,979         19.39         0.46           186         3356         55.42         116         4665         24.87         0.5           94         5898         15.94         53         7052         7.52         0.49           295         5635         52.35         183         9240         19.81         0.41           247         1612         153.26         151         2352         64.20         0.5           368         7747         47.50         209         10,880         19.21         0.44           218         4280         50.93         144         6293         22.88         0.49           50         1118         44.73         34         1471         23.11         0.57           214         6442         33.22         129         8991         14.35         0.46           315         4907         64.20         196         7169         27.34         0.47           107         1797         59.55         62         2483         24.97         0.47 </td <td>N PY IR n PY IR cHR (95% CI)  450 9789 45.97 271 13,979 19.39 0.46 (0.39, 0.53) *** 186 3356 55.42 116 4665 24.87 0.5 (0.4, 0.63) ***  94 5898 15.94 53 7052 7.52 0.49 (0.35, 0.69) *** 295 5635 52.35 183 9240 19.81 0.41 (0.34, 0.5) *** 247 1612 153.26 151 2352 64.20 0.5 (0.41, 0.62) ***  368 7747 47.50 209 10,880 19.21 0.44 (0.37, 0.53) *** 218 4280 50.93 144 6293 22.88 0.49 (0.4, 0.61) *** 50 1118 44.73 34 1471 23.11 0.57 (0.37, 0.88) *  214 6442 33.22 129 8991 14.35 0.46 (0.37, 0.58) *** 107 1797 59.55 62 2483 24.97 0.47 (0.4, 0.57) *** 107 1797 59.55 62 2483 24.97 0.47 (0.35, 0.65) ***  471 8692 54.19 281 12,365 22.73 0.47 (0.4, 0.54) *** 48 1168 41.10 27 1527 17.69 0.48 (0.3, 0.76) ***  566 12,520 45.21 342 17,534 19.50 0.47 (0.41, 0.54) *** 70 625 111.91 45 1110 40.55 0.43 (0.29, 0.62) ***  572 12,524 43.14 304 17,145 17.73 0.45 (0.39, 0.52) ****  580 12,054 43.14 304 17,145 17.73 0.45 (0.39, 0.52) ****</td> <td>N PY IR n PY IR cHR (95% CI) p-Value  450 9789 45.97 271 13,979 19.39 0.46 (0.39, 0.53) **** &lt;0.001 186 3356 55.42 116 4665 24.87 0.5 (0.4, 0.63) **** &lt;0.001  94 5898 15.94 53 7052 7.52 0.49 (0.35, 0.69) **** &lt;0.001 295 5635 52.35 183 92.40 19.81 0.41 (0.34, 0.5) *** &lt;0.001  247 1612 153.26 151 2352 64.20 0.5 (0.41, 0.62) **** &lt;0.001  218 4280 50.93 144 6293 22.88 0.49 (0.4, 0.61) **** &lt;0.001 218 4280 50.93 144 6293 22.88 0.49 (0.4, 0.61) *** &lt;0.001  214 6442 33.22 129 8991 14.35 0.46 (0.37, 0.58) *** &lt;0.001 107 1797 59.55 62 2483 24.97 0.47 (0.4, 0.57) *** &lt;0.001 117 3285 35.62 79 4752 16.62 0.5 (0.37, 0.66) *** &lt;0.001 48 1168 41.10 27 1527 17.69 0.48 (0.3, 0.76) ** &lt;0.001 259 2227 116.28 150 3781 39.67 0.41 (0.34, 0.5) *** &lt;0.001 250 11,739 44.55 306 16,397 18.66 0.46 (0.4, 0.53) *** &lt;0.001 113 1406 80.36 81 2247 36.05 0.51 (0.38, 0.68) *** &lt;0.001 150 12,054 43.14 304 17,145 17.73 0.45 (0.39, 0.52) *** &lt;0.001</td> <td>N PY IR n PY IR cHR (95% CI) p-Value aHR †  450 9789 45.97 271 13,979 19.39 0.46 (0.39,0.53)**** &lt;0.001 0.37 186 3356 55.42 116 4665 24.87 0.5 (0.4,0.63)**** &lt;0.001 0.32 94 5898 15.94 53 7052 7.52 0.49 (0.35,0.69)*** &lt;0.001 0.32 295 5635 52.35 183 9240 19.81 0.41 (0.34,0.5)*** &lt;0.001 0.35 247 1612 153.26 151 2352 64.20 0.5 (0.41,0.62)*** &lt;0.001 0.37 368 7747 47.50 209 10,880 19.21 0.44 (0.37,0.53)*** &lt;0.001 0.35 218 4280 50.93 144 6293 22.88 0.49 (0.4,0.61)*** &lt;0.001 0.38 50 1118 44.73 34 1471 23.11 0.57 (0.37,0.88)* 0.0113 0.84 214 6442 33.22 129 8991 14.35 0.46 (0.37,0.58)*** &lt;0.001 0.3 315 4907 64.20 196 7169 27.34 0.47 (0.4,0.57)*** &lt;0.001 0.36 107 1797 59.55 62 2483 24.97 0.47 (0.4,0.57)*** &lt;0.001 0.36 471 8692 54.19 281 12,365 22.73 0.47 (0.4,0.57)*** &lt;0.001 0.36 117 3285 35.62 79 4752 16.62 0.5 (0.37,0.66)*** &lt;0.001 0.34 48 1168 41.10 27 1527 17.69 0.48 (0.3,0.76)** &lt;0.001 0.34 48 1168 41.10 27 1527 17.69 0.48 (0.3,0.76)** &lt;0.001 0.37 70 625 111.91 45 1110 40.55 0.43 (0.29,0.62)*** &lt;0.001 0.39 259 2227 116.28 150 3781 39.67 0.41 (0.34,0.5)*** &lt;0.001 0.39 520 12,054 43.14 304 17,145 17.73 0.45 (0.39,0.52)*** &lt;0.001 0.39 520 12,054 43.14 304 17,145 17.73 0.45 (0.39,0.52)*** &lt;0.001 0.35</td> <td>N PY IR n PY IR characteristic Color of the color of the</td>	N PY IR n PY IR cHR (95% CI)  450 9789 45.97 271 13,979 19.39 0.46 (0.39, 0.53) *** 186 3356 55.42 116 4665 24.87 0.5 (0.4, 0.63) ***  94 5898 15.94 53 7052 7.52 0.49 (0.35, 0.69) *** 295 5635 52.35 183 9240 19.81 0.41 (0.34, 0.5) *** 247 1612 153.26 151 2352 64.20 0.5 (0.41, 0.62) ***  368 7747 47.50 209 10,880 19.21 0.44 (0.37, 0.53) *** 218 4280 50.93 144 6293 22.88 0.49 (0.4, 0.61) *** 50 1118 44.73 34 1471 23.11 0.57 (0.37, 0.88) *  214 6442 33.22 129 8991 14.35 0.46 (0.37, 0.58) *** 107 1797 59.55 62 2483 24.97 0.47 (0.4, 0.57) *** 107 1797 59.55 62 2483 24.97 0.47 (0.35, 0.65) ***  471 8692 54.19 281 12,365 22.73 0.47 (0.4, 0.54) *** 48 1168 41.10 27 1527 17.69 0.48 (0.3, 0.76) ***  566 12,520 45.21 342 17,534 19.50 0.47 (0.41, 0.54) *** 70 625 111.91 45 1110 40.55 0.43 (0.29, 0.62) ***  572 12,524 43.14 304 17,145 17.73 0.45 (0.39, 0.52) ****  580 12,054 43.14 304 17,145 17.73 0.45 (0.39, 0.52) ****	N PY IR n PY IR cHR (95% CI) p-Value  450 9789 45.97 271 13,979 19.39 0.46 (0.39, 0.53) **** <0.001 186 3356 55.42 116 4665 24.87 0.5 (0.4, 0.63) **** <0.001  94 5898 15.94 53 7052 7.52 0.49 (0.35, 0.69) **** <0.001 295 5635 52.35 183 92.40 19.81 0.41 (0.34, 0.5) *** <0.001  247 1612 153.26 151 2352 64.20 0.5 (0.41, 0.62) **** <0.001  218 4280 50.93 144 6293 22.88 0.49 (0.4, 0.61) **** <0.001 218 4280 50.93 144 6293 22.88 0.49 (0.4, 0.61) *** <0.001  214 6442 33.22 129 8991 14.35 0.46 (0.37, 0.58) *** <0.001 107 1797 59.55 62 2483 24.97 0.47 (0.4, 0.57) *** <0.001 117 3285 35.62 79 4752 16.62 0.5 (0.37, 0.66) *** <0.001 48 1168 41.10 27 1527 17.69 0.48 (0.3, 0.76) ** <0.001 259 2227 116.28 150 3781 39.67 0.41 (0.34, 0.5) *** <0.001 250 11,739 44.55 306 16,397 18.66 0.46 (0.4, 0.53) *** <0.001 113 1406 80.36 81 2247 36.05 0.51 (0.38, 0.68) *** <0.001 150 12,054 43.14 304 17,145 17.73 0.45 (0.39, 0.52) *** <0.001	N PY IR n PY IR cHR (95% CI) p-Value aHR †  450 9789 45.97 271 13,979 19.39 0.46 (0.39,0.53)**** <0.001 0.37 186 3356 55.42 116 4665 24.87 0.5 (0.4,0.63)**** <0.001 0.32 94 5898 15.94 53 7052 7.52 0.49 (0.35,0.69)*** <0.001 0.32 295 5635 52.35 183 9240 19.81 0.41 (0.34,0.5)*** <0.001 0.35 247 1612 153.26 151 2352 64.20 0.5 (0.41,0.62)*** <0.001 0.37 368 7747 47.50 209 10,880 19.21 0.44 (0.37,0.53)*** <0.001 0.35 218 4280 50.93 144 6293 22.88 0.49 (0.4,0.61)*** <0.001 0.38 50 1118 44.73 34 1471 23.11 0.57 (0.37,0.88)* 0.0113 0.84 214 6442 33.22 129 8991 14.35 0.46 (0.37,0.58)*** <0.001 0.3 315 4907 64.20 196 7169 27.34 0.47 (0.4,0.57)*** <0.001 0.36 107 1797 59.55 62 2483 24.97 0.47 (0.4,0.57)*** <0.001 0.36 471 8692 54.19 281 12,365 22.73 0.47 (0.4,0.57)*** <0.001 0.36 117 3285 35.62 79 4752 16.62 0.5 (0.37,0.66)*** <0.001 0.34 48 1168 41.10 27 1527 17.69 0.48 (0.3,0.76)** <0.001 0.34 48 1168 41.10 27 1527 17.69 0.48 (0.3,0.76)** <0.001 0.37 70 625 111.91 45 1110 40.55 0.43 (0.29,0.62)*** <0.001 0.39 259 2227 116.28 150 3781 39.67 0.41 (0.34,0.5)*** <0.001 0.39 520 12,054 43.14 304 17,145 17.73 0.45 (0.39,0.52)*** <0.001 0.39 520 12,054 43.14 304 17,145 17.73 0.45 (0.39,0.52)*** <0.001 0.35	N PY IR n PY IR characteristic Color of the

Int. J. Environ. Res. Public Health **2023**, 20, 1690

Table 3. Cont.

Variables	Migraine without Acupuncture			Migrair	Migraine with Acupuncture							
	N	PY	IR	n	PY	IR	cHR	(95% CI)	<i>p</i> -Value	aHR †	(95% CI)	<i>p</i> -Value
Head injury												
No	611	12,875	47.46	375	18,082	20.74	0.48	(0.42, 0.54) ***	< 0.001	0.37	(0.32, 0.42) ***	< 0.001
Yes	25	270	92.58	12	562	21.36	0.29	(0.15, 0.58) ***	< 0.001	0.12	(0.04, 0.41) ***	< 0.001
Parkinson's disease												
No	628	13,131	47.83	380	18,555	20.48	0.47	(0.41, 0.53) ***	< 0.001	0.37	(0.32, 0.42) ***	< 0.001
Yes	8	15	548.01	7	89	78.31	0.33	(0.12, 0.92) *	0.0336	0	(0,0)	0.9997
Chronic kidney disease								, , ,			, , ,	
No	596	12,701	46.93	361	18,014	20.04	0.47	(0.41, 0.53) ***	< 0.001	0.37	(0.32, 0.42) ***	< 0.001
Yes	40	444	90.00	26	630	41.26	0.53	(0.32, 0.87) *	0.012	0.32	(0.17, 0.59) ***	< 0.001
Mental disorders								, , ,			,	
No	325	7615	42.68	173	11,049	15.66	0.4	(0.34, 0.49) ***	< 0.001	0.3	(0.24, 0.36) ***	< 0.001
Yes	311	5530	56.24	214	7594	28.18	0.55	(0.46, 0.65) ***	< 0.001	0.44	(0.37, 0.52) ***	< 0.001
Medication								, ,			, , ,	
0–1	137	371	368.79	77	1152	66.83	0.32	(0.24, 0.43) ***	< 0.001	0.35	(0.26, 0.47) ***	< 0.001
2–3	344	6425	53.54	178	9986	17.82	0.37	(0.31, 0.45) ***	< 0.001	0.38	(0.31, 0.45) ***	< 0.001
>3	155	6348	24.42	132	7505	17.59	0.72	(0.57, 0.91) **	0.0064	0.57	(0.45, 0.73) ***	< 0.001

PY: person-years; IR: incidence rate per 1000 person-years; cHR: crude hazard ratio; aHR: adjusted hazard ratio;  $^{\dagger}$  adjusted by sex, age, urbanization level, occupation, income, comorbidities, and medication;  $^{*}$ : p-value < 0.05;  $^{**}$  p < 0.01,  $^{***}$  p < 0.001.  $^{\#}$  New Taiwan Dollar (NTD), 1 NTD is equal to 0.03 USD.  $^{\ddagger}$  The urbanization level was divided by the population density of the residential area into 3 levels, in which level 1 was the most urbanized and level 3 was the least urbanized.  $^{\&}$  Other occupation categories included those who were primarily retired, unemployed, and low-income populations.

**Table 4.** Incidence rates, hazard ratios, and confidence intervals of ischemic and hemorrhagic strokes in patients with migraines who did and did not receive acupuncture treatment.

	Migraine	without Acup	uncture	Migraine with Acupuncture								
Variables	n	PY	IR	n	PY	IR	cHR	(95% CI)	<i>p</i> -Value	aHR †	(95% CI)	<i>p</i> -Value
Ischemic stroke	621	13,227	46.95	379	18,656	20.32	0.47	(0.42, 0.54) ***	< 0.001	0.41	(0.36, 0.46) ***	< 0.001
Hemorrhagic stroke	73	13,421	5.44	46	18,793	2.45	0.46	(0.32, 0.67) ***	< 0.001	0.36	(0.25, 0.53) ***	< 0.001

PY: person-years; IR: incidence rate per 1000 person-years; cHR: crude hazard ratio; aHR: adjusted hazard ratio; † djusted by sex, age, urbanization level, occupation, income, comorbidities, and medication; \*\*\* p < 0.001.

### 4. Discussion

Our study attempted to use a large real-world dataset with long-term follow-up to determine whether acupuncture treatment could significantly reduce the risk of stroke development in migraineurs. The results of the study found that acupuncture treatment reduces the risk of strokes in patients with migraines by approximately 60%, showing that this treatment method has a good protective effect against strokes.

The Taiwanese government started creating the country's NHI program in 1995 to cover the entire public insurance system. At present, NHI coverage reaches more than 99% of the 23 million residents of Taiwan. The NHI program includes both Western and traditional Chinese medicine and provides representative and empirical health insurance data for use in research [20,21]. The Central Health Insurance Bureau has been building the NHIRD since 1998 and has provided value-added services for its data to facilitate related medical and public health research since 2000. The NHIRD provides a large population sample: real-world evidence that can eliminate bias from limited sample sizes. In addition, the database presents a long-term follow-up window of more than 10 years, which makes it easier for researchers to study the development of chronic diseases and the risk of related diseases. In Taiwan, traditional Chinese medicine treatment, which includes acupuncture, is only performed by qualified traditional Chinese medicine doctors after complete training and national certification. In clinical practice, this modality is completely complementary to modern medicine and ensures that patients are provided with the most suitable diagnoses and treatments. The relevant treatment records are included in the NHIRD. Therefore, we consider this database to be a trustworthy research tool from which we developed unbiased real-world evidence for our study.

We found no difference in stroke risk between women and men. This appears to contradict many previous studies on migraines and strokes, which reported a predominance of stroke risks in women [10,22]. We speculate that several reasons are behind this. Most studies report that female migraine patients are more prone to ischemic strokes than their male counterparts, but the relationship with hemorrhagic stroke remains controversial [23–26]. However, our study evaluated all types of strokes, which might have influenced our results. The prevalence of migraines in men is approximately one-third that of women, and the association with strokes is more uncertain in men than in women [27], especially in our limited paired sample. In addition, we did not include migraine-free male and female populations with strokes for comparison, which might also have led to different results. However, acupuncture was associated with reduced stroke risk in both male and female patients with migraines. Patients with migraines in the present study who were aged 40-59 years and >59 years had a higher risk of strokes than younger populations, suggesting that the risk of a stroke increases with increasing age. This finding is similar in general populations without migraines [28,29], indicating that aging may be a pivotal factor that increases the incidence of strokes in the migraine population. We found that acupuncture significantly reduced the risk of strokes in all age groups of patients with migraines and that patients of older ages had a higher risk of strokes. Thus, we infer that acupuncture treatment offers a very good and substantial protective benefit to older patients with migraines.

In our study, among the listed comorbidities that were associated with migraines, hypertension, coronary artery disease, head injury, Parkinson's disease, and mental disorders were independently found to significantly increase the risk of stroke. Hypertension is the most common risk factor for stroke, high blood pressure can increase the risk of strokes by four times, and routine blood pressure management is very important [30,31]. Previous studies have shown that a substantial proportion of stroke patients have preclinical coronary artery disease and that there is a clear relationship between cerebral and coronary atherosclerosis, both in terms of location and burden [32]. A meta-analysis showed that traumatic brain injury was an independent risk factor for strokes, regardless of the severity or type of trauma [33]. A nationwide cohort study found that the head injury group had a significantly higher stroke risk than the control group (adjusted HR 1.65).

Moreover, in the head injury group, the cumulative incidences of ischemic and hemorrhagic strokes were higher than those in the control group (8.9% vs. 5.8% and 2.7% vs. 1.6%, respectively), indicating that a head injury is an independent risk factor for ischemic and hemorrhagic strokes [34]. Similarly, another study calculated an HR of 2.37 for strokes in the Parkinson's disease group compared with the non-Parkinson's disease group during 3 years of follow-up, indicating that patients with Parkinson's disease have a significantly increased risk of ischemic stroke [35]. A meta-analysis of 17 prospective studies involving 206,641 participants showed a significant positive association between depression and the subsequent risk of a stroke after adjusting for potential confounders [36]. Additionally, in a systematic review and meta-analysis of eight studies including 950,759 patients, researchers observed a 24% increased stroke risk in people with anxiety disorders compared to the general population [37]. We found that acupuncture could potentially reduce the incidence of stroke in patients with these underlying comorbidities. Many clinical and experimental studies have been published that show the benefits of acupuncture treatment for treating hypertension [38,39], coronary artery disease [40,41], head injury [42,43], Parkinson's disease [44,45], and mental disorders [46,47]. Since the above-mentioned potential comorbidities of migraines increase the risk of strokes, and acupuncture shows an independent benefit for patients with these comorbidities, we can consider acupuncture as a treatment that can reduce the risk of strokes in patients with migraines, perhaps by aiding in the control of any accompanying comorbidities. Moreover, while no existing preventive medication for migraines reduces future strokes, our study found that participants who took more medications for migraines had a lower risk of stroke. This result deserves further clarification and may be related to the fact that patients who took more medication, either because they experienced more pain or because they had less control, were likely to return more often for medical advice and to make more aggressive changes to their diets and lifestyles. The habit of taking care of the body in this way may prevent strokes and other cerebrovascular diseases. Nevertheless, we determined that regardless of the quantity of migraine medication taken, it has a positive effect on stroke prevention when combined with acupuncture.

Although the mechanisms by which migraines increase the risk of strokes are not fully understood, several associated pathological mechanisms have been discovered. One study suggested that migraines may directly cause migraine infarction by inducing cerebral microcirculatory vasoconstriction, cerebral large vessel spasms, and vascular endothelial-related hypercoagulability [48]. Another study mentioned that the hypoperfusion of the brain that occurs during a migraine attack can lead to electrical abnormalities that cause a phenomenon called "spreading depression", which can lead to strokes [49]. Acupuncture treatment has been proven beneficial in the clinical treatment of migraines [50,51], and in effectively reducing stroke risks in patients with depression [18], and fibromyalgia [52]. Since migraines and strokes are heterogeneous cerebrovascular diseases with common mechanisms, it is reasonable to hypothesize that when acupuncture is used to treat patients with migraines, it would be beneficial in reducing the risk of a stroke.

Our present study clearly illustrates that acupuncture complements modern medical treatment to bring about a reduced incidence of stroke development in patients with migraines. The question then arises of how acupuncture is able to achieve such an effect. In the future, more basic experiments should be conducted to clarify the mechanism of action of acupuncture to support our clinical data.

Our study had several limitations. (1) The effect of acupuncture treatment on the risk of strokes in migraine patients of different degrees was not explored. Quantifications of actual severity and frequency of headache attacks in migraineurs were not recorded in the NHIRD medical records. However, the subcategories of migraine ICD codes, such as refractory migraine, non-refractory migraine, episodic migraine, and chronic migraine, could guide further research on this topic. In addition, we did not clarify the association between the number, frequency, timing, and duration of acupuncture treatment in patients with migraines and the risk of a stroke. Future studies could examine the differences in the risk

of strokes among patients receiving acupuncture for the first time versus those who have tried other medications, or compare the stroke risk of patients with acupuncture-refractory migraines versus the stroke risk of patients with non-refractory migraines. Furthermore, aura is a clear risk factor for strokes in migraineurs [7]. We did not divide patients with migraines into subgroups with and without aura. Therefore, studies including larger datasets are necessary to test whether acupuncture leads to an overestimation of stroke risk reduction due to the selection bias resulting from using it more in migraineurs without aura than in those with aura. (2) In addition to the listed comorbidities associated with migraines affecting the risk of a stroke in this study, some factors deserve special consideration. The lifestyle and behavior patterns of migraine patients are also important factors affecting the risk of a stroke. For example, smoking and oral contraceptive pill use are known major contributors to the high risk of strokes in migraineurs [24,53]. However, we did not include these as comorbid factors that could have affected the outcome. The association of these behaviors with seeking acupuncture treatment also remains unclear. The Taiwan Biobank is a large biomedical research database that has collected rich lifestyle factors and genetic variant data from more than 130,000 participants and can be linked with the NHIRD [54,55]. Further analysis on this basis is warranted in the future. (3) In Taiwan, acupuncture treatments provided by a small number of traditional Chinese medicine doctors are self-paid and, therefore, not covered by the NHI. If patients sought these services, bias may have been introduced in our data analysis. (4) Clinical indicators are very important for evaluating the efficacy of acupuncture. Unfortunately, since the acupoints are not recorded in the database, it is impossible to analyze the correlation between the choice of acupoints in patients with migraines and the risk of stroke. Although a number of systematic reviews have reported the benefits of acupuncture for migraines, many of the studies were considered to be of low or critically low quality based on the assessment of multiple systematic review (AMSTAR) criteria [56]. We believe that rigorous large-scale prospective clinical trials should be conducted in the future. In addition, further animal experiments are needed to elucidate the mechanism through which acupuncture achieves its efficacy.

### 5. Conclusions

This 19-year-long retrospective study showed that migraineurs who received acupuncture treatment had significantly lower stroke risks, after adjustment for covariates, compared with migraineurs who did not receive acupuncture treatment. These findings support the benefit of using appropriate acupuncture treatment in patients with migraines to prevent long-term stroke risk. These results may help inform clinicians and public health policymakers.

**Author Contributions:** Conceptualization, C.-C.L. and J.-M.L.; methodology, C.-H.C. and F.-J.T.; software, Y.-H.S.; validation, Y.-H.S.; formal analysis, C.-C.L. and Y.-H.S.; investigation, F.-J.T.; resources, F.-J.T.; writing—original draft, C.-C.L. and C.-H.C.; writing—review and editing, J.-M.L.; Supervision, J.-M.L.; project administration, F.-J.T. and J.-M.L. All authors have read and agreed to the published version of the manuscript.

**Funding:** This study is supported in part by the Ministry of Science and Technology (MOST 111-2321-B-039-005), China Medical University Hospital (DMR-111-105). No additional external funding was received for this study.

**Institutional Review Board Statement:** This study was approved by the Institutional Review Board of the China Medical University in central Taiwan (CMUH110-REC1-038(CR-1), 10 February 2022).

Informed Consent Statement: Not applicable.

**Data Availability Statement:** The data in this study are available to other researchers upon request.

**Acknowledgments:** We are grateful to the Health Data Science Center, China Medical University Hospital for providing administrative, technical, and funding support.

**Conflicts of Interest:** The authors declare no conflict of interest. The funders had no role in the study design, data collection, and analysis, the decision to publish, or the preparation of the manuscript.

# References

- 1. Ashina, M.; Katsarava, Z.; Do, T.P.; Buse, D.C.; Pozo-Rosich, P.; Özge, A.; Krymchantowski, A.V.; Lebedeva, E.R.; Ravishankar, K.; Yu, S.; et al. Migraine: Epidemiology and systems of care. *Lancet* **2021**, *397*, 1485–1495. [CrossRef] [PubMed]
- 2. Burch, R.C.; Buse, D.C.; Lipton, R.B. Migraine: Epidemiology, Burden, and Comorbidity. *Neurol. Clin.* **2019**, *37*, 631–649. [CrossRef] [PubMed]
- 3. Goadsby, P.J.; Holland, P.R. An Update: Pathophysiology of Migraine. Neurol. Clin. 2019, 37, 651-671. [CrossRef] [PubMed]
- 4. Antonaci, F.; Ghiotto, N.; Wu, S.; Pucci, E.; Costa, A. Recent advances in migraine therapy. *Springerplus* **2016**, *5*, 637. [CrossRef] [PubMed]
- 5. Puledda, F.; Shields, K. Non-Pharmacological Approaches for Migraine. Neurotherapeutics 2018, 15, 336–345. [CrossRef]
- 6. Feigin, V.L.; Nguyen, G.; Cercy, K.; Johnson, C.O.; Alam, T.; Parmar, P.G.; Abajobir, A.A.; Abate, K.H.; Abd-Allah, F.; Abejie, A.N.; et al. Global, Regional, and Country-Specific Lifetime Risks of Stroke, 1990 and 2016. N. Engl. J. Med. 2018, 379, 2429–2437. [CrossRef]
- 7. Sacco, S.; Kurth, T. Migraine and the risk for stroke and cardiovascular disease. Curr. Cardiol. Rep. 2014, 16, 524. [CrossRef]
- 8. Peng, K.P.; Chen, Y.T.; Fuh, J.L.; Tang, C.H.; Wang, S.J. Migraine and incidence of ischemic stroke: A nationwide population-based study. *Cephalalgia* **2017**, *37*, 327–335. [CrossRef]
- 9. Siao, W.Z.; Su, C.H.; Kuan, Y.H.; Tsai, T.H.; Huan, K.H.; Lee, C.Y. Risk of peripheral artery disease and stroke in migraineurs with or without aura: A nationwide population-based cohort study. *Int. J. Med. Sci.* **2022**, *19*, 1163–1172. [CrossRef]
- 10. Øie, L.R.; Kurth, T.; Gulati, S.; Dodick, D.W. Migraine and risk of stroke. *J. Neurol. Neurosurg. Psychiatry* **2020**, 91, 593–604. [CrossRef]
- 11. Supasiri, T.; Jariengprasert, C.; Phithaksilp, M.; Sangtongpanichakul, P.; Anotayanonth, S.; Buranatawonsom, T.; Pongpirul, K. A randomized controlled clinical trial comparing different numbers of acupuncture sessions for migraine. *Acupunct. Med.* **2022**, 40, 215–223. [CrossRef]
- 12. Li, Y.X.; Xiao, X.L.; Zhong, D.L.; Luo, L.J.; Yang, H.; Zhou, J.; He, M.X.; Shi, L.H.; Li, J.; Zheng, H.; et al. Effectiveness and Safety of Acupuncture for Migraine: An Overview of Systematic Reviews. *Pain Res. Manag.* 2020, 2020, 3825617. [CrossRef]
- 13. Zhao, L.; Chen, J.; Li, Y.; Sun, X.; Chang, X.; Zheng, H.; Gong, B.; Huang, Y.; Yang, M.; Wu, X.; et al. The Long-term Effect of Acupuncture for Migraine Prophylaxis: A Randomized Clinical Trial. *JAMA Intern. Med.* **2017**, *177*, 508–515. [CrossRef]
- 14. Mayrink, W.C.; Garcia, J.B.S.; Dos Santos, A.M.; Nunes, J.; Mendonça, T.H.N. Effectiveness of Acupuncture as Auxiliary Treatment for Chronic Headache. *J. Acupunct. Meridian Stud.* **2018**, *11*, 296–302. [CrossRef]
- 15. Liu, L.; Zhao, L.P.; Zhang, C.S.; Zeng, L.; Wang, K.; Zhao, J.; Wang, L.; Jing, X.; Li, B. Acupuncture as prophylaxis for chronic migraine: A protocol for a single-blinded, double-dummy randomised controlled trial. *BMJ Open* **2018**, *8*, e020653. [CrossRef]
- 16. Yang, A.; Wu, H.M.; Tang, J.L.; Xu, L.; Yang, M.; Liu, G.J. Acupuncture for stroke rehabilitation. *Cochrane Database Syst. Rev.* **2016**, Cd004131. [CrossRef]
- 17. Li, L.; Zhu, W.; Lin, G.; Chen, C.; Tang, D.; Lin, S.; Weng, X.; Xie, L.; Lu, L.; Li, W. Effects of Acupuncture in Ischemic Stroke Rehabilitation: A Randomized Controlled Trial. *Front. Neurol.* **2022**, *13*, 897078. [CrossRef]
- 18. Chen, L.Y.; Yen, H.R.; Sun, M.F.; Lin, C.L.; Chiang, J.H.; Lee, Y.C. Acupuncture treatment is associated with a decreased risk of developing stroke in patients with depression: A propensity-score matched cohort study. *J. Affect. Disord.* **2019**, 250, 298–306. [CrossRef]
- 19. Li, X.; Wang, Q. Acupuncture therapy for stroke patients. Int. Rev. Neurobiol. 2013, 111, 159–179. [CrossRef]
- 20. Wu, T.Y.; Majeed, A.; Kuo, K.N. An overview of the healthcare system in Taiwan. Lond. J. Prim. Care 2010, 3, 115–119. [CrossRef]
- 21. Lee, P.C.; Kao, F.Y.; Liang, F.W.; Lee, Y.C.; Li, S.T.; Lu, T.H. Existing Data Sources in Clinical Epidemiology: The Taiwan National Health Insurance Laboratory Databases. *Clin. Epidemiol.* **2021**, *13*, 175–181. [CrossRef] [PubMed]
- 22. Etminan, M.; Takkouche, B.; Isorna, F.C.; Samii, A. Risk of ischaemic stroke in people with migraine: Systematic review and meta-analysis of observational studies. *BMJ* **2005**, *330*, 63. [CrossRef] [PubMed]
- 23. Tietjen, G.E.; Maly, E.F. Migraine and Ischemic Stroke in Women. A Narrative Review. Headache 2020, 60, 843–863. [CrossRef]
- 24. Sacco, S.; Merki-Feld, G.S.; Ægidius, K.L.; Bitzer, J.; Canonico, M.; Kurth, T.; Lampl, C.; Lidegaard, Ø.; Anne MacGregor, E.; MaassenVanDenBrink, A.; et al. Hormonal contraceptives and risk of ischemic stroke in women with migraine: A consensus statement from the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC). J. Headache Pain 2017, 18, 108, Erratum in J. Headache Pain 2018, 19, 81. [CrossRef] [PubMed]
- 25. Hu, X.; Zhou, Y.; Zhao, H.; Peng, C. Migraine and the risk of stroke: An updated meta-analysis of prospective cohort studies. *Neurol. Sci.* **2017**, *38*, 33–40. [CrossRef] [PubMed]
- 26. Gaist, D.; González-Pérez, A.; Ashina, M.; Rodríguez, L.A. Migraine and risk of hemorrhagic stroke: A study based on data from general practice. *J. Headache Pain* **2014**, *15*, 74. [CrossRef]
- 27. Schürks, M.; Rist, P.M.; Bigal, M.E.; Buring, J.E.; Lipton, R.B.; Kurth, T. Migraine and cardiovascular disease: Systematic review and meta-analysis. *BMJ* **2009**, 339, b3914. [CrossRef]
- 28. Wu, C.Y.; Wu, H.M.; Lee, J.D.; Weng, H.H. Stroke risk factors and subtypes in different age groups: A hospital-based study. *Neurol. India* **2010**, *58*, 863–868. [CrossRef]

- 29. Kelly-Hayes, M. Influence of age and health behaviors on stroke risk: Lessons from longitudinal studies. *J. Am. Geriatr. Soc.* **2010**, 58 (Suppl. 2), S325–S328. [CrossRef]
- 30. Wajngarten, M.; Silva, G.S. Hypertension and Stroke: Update on Treatment. Eur. Cardiol. 2019, 14, 111–115. [CrossRef]
- 31. Arboix, A. Cardiovascular risk factors for acute stroke: Risk profiles in the different subtypes of ischemic stroke. *World J. Clin. Cases* **2015**, *3*, 418–429. [CrossRef]
- 32. Yoo, J.; Yang, J.H.; Choi, B.W.; Kim, Y.D.; Nam, H.S.; Choi, H.Y.; Cho, H.J.; Lee, H.S.; Cha, M.J.; Choi, D.; et al. The frequency and risk of preclinical coronary artery disease detected using multichannel cardiac computed tomography in patients with ischemic stroke. *Cerebrovasc. Dis.* 2012, 33, 286–294. [CrossRef]
- 33. Turner, G.M.; McMullan, C.; Aiyegbusi, O.L.; Bem, D.; Marshall, T.; Calvert, M.; Mant, J.; Belli, A. Stroke risk following traumatic brain injury: Systematic review and meta-analysis. *Int. J. Stroke* **2021**, *16*, 370–384. [CrossRef]
- 34. Liu, S.W.; Huang, L.C.; Chung, W.F.; Chang, H.K.; Wu, J.C.; Chen, L.F.; Chen, Y.C.; Huang, W.C.; Cheng, H.; Lo, S.S. Increased Risk of Stroke in Patients of Concussion: A Nationwide Cohort Study. *Int. J. Environ. Res. Public Health* **2017**, 14, 230. [CrossRef]
- 35. Huang, Y.P.; Chen, L.S.; Yen, M.F.; Fann, C.Y.; Chiu, Y.H.; Chen, H.H.; Pan, S.L. Parkinson's disease is related to an increased risk of ischemic stroke-a population-based propensity score-matched follow-up study. *PLoS ONE* **2013**, *8*, e68314. [CrossRef]
- 36. Dong, J.Y.; Zhang, Y.H.; Tong, J.; Qin, L.Q. Depression and risk of stroke: A meta-analysis of prospective studies. *Stroke* **2012**, *43*, 32–37. [CrossRef]
- 37. Pérez-Piñar, M.; Ayerbe, L.; González, E.; Mathur, R.; Foguet-Boreu, Q.; Ayis, S. Anxiety disorders and risk of stroke: A systematic review and meta-analysis. *Eur. Psychiatry* **2017**, *41*, 102–108. [CrossRef]
- 38. Zhao, X.F.; Hu, H.T.; Li, J.S.; Shang, H.C.; Zheng, H.Z.; Niu, J.F.; Shi, X.M.; Wang, S. Is Acupuncture Effective for Hypertension? A Systematic Review and Meta-Analysis. *PLoS ONE* **2015**, *10*, e0127019. [CrossRef] [PubMed]
- 39. Li, J.; Sun, M.; Ye, J.; Li, Y.; Jin, R.; Zheng, H.; Liang, F. The Mechanism of Acupuncture in Treating Essential Hypertension: A Narrative Review. *Int. J. Hypertens.* **2019**, 2019, 8676490. [CrossRef]
- 40. Meng, J. The effects of acupuncture in treatment of coronary heart diseases. J. Tradit. Chin. Med. 2004, 24, 16–19.
- 41. Huang, X.; Guo, S.; Li, F.; Tan, X.; Cai, Q.; Wang, H.; Chen, P.; Wang, G.; Ma, X. Acupuncture as an Adjunctive Treatment for Angina Due to Coronary Artery Disease: A Meta-Analysis. *Med. Sci. Monit.* **2019**, 25, 1263–1274. [CrossRef] [PubMed]
- 42. Tan, L.; Zeng, L.; Wang, N.; Deng, M.; Chen, Y.; Ma, T.; Zhang, L.; Xu, Z. Acupuncture to Promote Recovery of Disorder of Consciousness after Traumatic Brain Injury: A Systematic Review and Meta-Analysis. *Evid. Based. Complement. Alternat. Med.* 2019, 2019, 5190515. [CrossRef] [PubMed]
- 43. Cavalli, L.; Briscese, L.; Cavalli, T.; Andre, P.; Carboncini, M.C. Role of Acupuncture in the Management of Severe Acquired Brain Injuries (sABIs). *Evid. Based. Complement. Alternat. Med.* **2018**, 2018, 8107508. [CrossRef] [PubMed]
- 44. Lee, S.H.; Lim, S. Clinical effectiveness of acupuncture on Parkinson disease: A PRISMA-compliant systematic review and meta-analysis. *Medicine* **2017**, *96*, e5836. [CrossRef] [PubMed]
- 45. Zhao, Y.; Zhang, Z.; Qin, S.; Fan, W.; Li, W.; Liu, J.; Wang, S.; Xu, Z.; Zhao, M. Acupuncture for Parkinson's Disease: Efficacy Evaluation and Mechanisms in the Dopaminergic Neural Circuit. *Neural Plast.* **2021**, 2021, 9926445. [CrossRef]
- 46. Bai, L.; Zhang, D.; Cui, T.T.; Li, J.F.; Gao, Y.Y.; Wang, N.Y.; Jia, P.L.; Zhang, H.Y.; Sun, Z.R.; Zou, W.; et al. Mechanisms Underlying the Antidepressant Effect of Acupuncture via the CaMK Signaling Pathway. *Front. Behav. Neurosci.* 2020, 14, 563698. [CrossRef]
- 47. Amorim, D.; Amado, J.; Brito, I.; Fiuza, S.M.; Amorim, N.; Costeira, C.; Machado, J. Acupuncture and electroacupuncture for anxiety disorders: A systematic review of the clinical research. *Complement. Ther. Clin. Pract.* **2018**, *31*, 31–37. [CrossRef]
- 48. Pezzini, A.; Del Zotto, E.; Giossi, A.; Volonghi, I.; Grassi, M.; Padovani, A. The migraine-ischemic stroke connection: Potential pathogenic mechanisms. *Curr. Mol. Med.* **2009**, *9*, 215–226. [CrossRef]
- 49. Hassan, M.; Belavadi, R.; Gudigopuram, S.V.R.; Raguthu, C.C.; Gajjela, H.; Kela, I.; Kakarala, C.L.; Modi, S.; Sange, I. Migraine and Stroke: In Search of Shared Pathways, Mechanisms, and Risk Factors. *Cureus* **2021**, *13*, e20202. [CrossRef]
- 50. Molsberger, A. The role of acupuncture in the treatment of migraine. CMAJ 2012, 184, 391–392. [CrossRef]
- 51. Urits, I.; Patel, M.; Putz, M.E.; Monteferrante, N.R.; Nguyen, D.; An, D.; Cornett, E.M.; Hasoon, J.; Kaye, A.D.; Viswanath, O. Acupuncture and Its Role in the Treatment of Migraine Headaches. *Neurol. Ther.* **2020**, *9*, 375–394. [CrossRef]
- 52. Huang, M.C.; Yen, H.R.; Lin, C.L.; Lee, Y.C.; Sun, M.F.; Wu, M.Y. Acupuncture decreased the risk of stroke among patients with fibromyalgia in Taiwan: A nationwide matched cohort study. *PLoS ONE* **2020**, *15*, e0239703. [CrossRef]
- 53. Zhang, Y.; Parikh, A.; Qian, S. Migraine and stroke. Stroke Vasc. Neurol. 2017, 2, 160–167. [CrossRef]
- 54. Lin, J.C.; Hsiao, W.W.; Fan, C.T. Transformation of the Taiwan Biobank 3.0: Vertical and horizontal integration. *J. Transl. Med.* **2020**, *18*, 304. [CrossRef]
- 55. Lin, W.Y. Lifestyle Factors and Genetic Variants on 2 Biological Age Measures: Evidence From 94 443 Taiwan Biobank Participants. J. Gerontol. A Biol. Sci. Med. Sci. 2022, 77, 1189–1198. [CrossRef]
- 56. Lu, T.T.; Lu, C.C.; Li, M.X.; Ke, L.X.; Cai, H.; Yang, K.H. Reporting and methodological quality of meta-analyses of acupuncture for patients with migraine: A methodological investigation with evidence map. *J. Integr. Med.* **2022**, 20, 213–220. [CrossRef]

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.